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hyperintensities in type 2 diabetic patients
Henrik Reinhard1*, Ellen Garde2, Arnold Skimminge2, Per Åkeson2, Thomas Zoëga Ramsøy2,7, Kaj Winther3,
Hans-Henrik Parving4,5, Peter Rossing1 and Peter K Jacobsen1,6Abstract: Elevated plasma N-terminal (NT)-proBNP from the heart as well as white matter hyperintensities (WMH) in
the brain predict cardiovascular (CV) mortality in the general population. The cause of poor prognosis associated
with elevated P-NT-proBNP is not known but WMH precede strokes in high risk populations. We assessed the
association between P-NT-proBNP and WMH or brain atrophy measured with magnetic resonance imaging (MRI) in
type 2 diabetic patients, and age-matched controls.
Methods and results: We measured P-NT-proBNP(ng/l) in 20 diabetic patients without prior stroke but with(n = 10)
or without(n = 10) asymptomatic coronary artery disease(CAD) in order to include patients with a wide-ranging CV
risk profile. All patients and 26 controls had a 3D MRI and brain volumes(ml) with WMH and brain parenchymal
fraction(BPF), an indicator of brain atrophy, were determined.
P-NT-proBNP was associated with WMH in linear regression analysis adjusted for CV risk factors(r = 0.94, p = 0.001)
and with BPF in univariate analysis(r = 0.57, p = 0.009). Patients divided into groups of increased P-NT-proBNP levels
were paralleled with increased WMH volumes(geometric mean[SD];(2.86[5.11] ml and 0.76[2.49] ml compared to
patients with low P-NT-proBNP 0.20[2.28] ml, p = 0.003)) and also when adjusted for age, sex and presence of CAD
(p = 0.017). The association was strengthened by CV risk factors and we did not find a common heart or brain
specific driver of both P-NT-proBNP and WMH. Patients and particular patients with CAD had higher WMH, however
no longer after adjustment for age and sex.
Conclusion: P-NT-proBNP was associated with WMH in type 2 diabetic patients, suggesting a linkage between
heart and brain disease.
Keywords: Type 2 diabetes, Plasma NT-proBNP, 3-D magnetic resonance imaging, White matter hyperintensities,
Brain parenchymal fractionIntroduction
Manifest atherosclerosis that includes strokes is the most
important determinant of the excessive morbidity and
mortality in patients with type 2 diabetes, especially in
patients with microalbuminuria [1]. Although medical
treatment aimed at reduction of established conventional
risk factors is effective in reducing the increased cardio-
vascular morbidity and mortality in patients with dia-
betes, there is still excess morbidity and mortality
compared to the background population [2]. Detection
of subclinical atherosclerotic manifestations in patients
with diabetes in order to be able to identify patients at* Correspondence: hrhl@dadlnet.dk
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reproduction in any medium, provided the orrisk and start appropriate intervention at an early stage
therefore seems evident.
Elevated plasma N-terminal-proBNP (P-NT-proBNP)
levels released from the heart as well as white matter
hyperintensities (WMH) in the brain are risk factors for
cardiovascular (CV) morbidity and mortality in the gen-
eral population [3,4]. We have previously identified P-
NT-proBNP as a powerful predictor of CV mortality
that included strokes in patients with type 2 diabetes [5].
The cause of poor prognosis seen in patients with ele-
vated P-NT-proBNP is not known, but P-NT-proBNP is
associated with the diagnosis of stroke in patients with
suspected acute cerebrovascular disease [6]. Further-
more, a recent study (25% had diabetes) showed that P-
NT-proBNP is highly elevated in patients with acute and
cardioemboli strokes compared to patients with otheral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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areas with high signal intensities on T2-weighted mag-
netic resonance imaging(MRI) are regarded as expres-
sions of chronic hypoperfusion [8]. Presence of WMH
portends a three-fold increased risk of stroke and two-
fold increased risk of dementia or mortality in the
general population [4]. WMH are together with brain at-
rophy regarded as surrogate markers for cerebral small
vessel disease. Cerebral small vessel disease is the most
prevalent asymptomatic neurological disease, its inci-
dence reported to be 6- to 10-fold that of symptomatic
stroke [9,10]. Whether P-NT-proBNP is associated with
WMH and/or brain atrophy in patients with type 2 dia-
betes, is not known. In this study, we assessed the asso-
ciation between P-NT-proBNP and WMH and/or brain
atrophy measured with MRI in type 2 diabetic without
prior history of stroke but with or without asymptomatic
coronary artery disease (CAD), and age and sex matched
controls.
Methods
Patient cohort and investigations
We have previously investigated the extent of asymp-
tomatic coronary artery disease as defined by myocardial
imaging (MPI) and/or coronary angiography (CAG) in a
study of 200 patients with type 2 diabetes and microal-
buminuria. The design and a selection of clinical mea-
surements of the study have previously been described
[11]. In the present study, we randomly selected 20
patients without previous clinical strokes but with or
without previously screen detected asymptomatic CAD
based on our previous study and in order to include
patients with a wide-ranging CV risk profile. We also
included 26 age and sex matched controls without
known diabetes or CAD. P-NT-proBNP was analysed by
an established immunoassay [5]. Tests for autonomic
neuropathy, heart rate variability assessed by the
expiration-inspiration variation of the heart rate and
somatic nerve function (vibratory perception threshold)
evaluated by biothesiometry, were performed.
The cardiovascular examinations have previously been
described [11-13]. In brief, carotid artery intima media
thickness (CIMT) was measured at the posterior wall ap-
proximately 20 mm proximal to the bifurcation bilat-
erally and calculated as the mean of CIMT on both
sides. Agaston coronary calcium score (CCS) was mea-
sured during a single breath hold using a 16
multidetector-row CT scanner with 3 mm slice thick-
ness. Transthoracic echocardiography was performed
using a Philips IE 33 machine. Significant CAD was
defined as the presence of significant myocardial perfu-
sion defects on MPI, and/or >70% coronary artery sten-
osis at CAG. The correlations between P-NT-proBNP,
CCS, MPI and CAG have previously been reported [11].All subjects underwent brain MRI (see below) and
patients were assessed with the Mini Mental Status
Examination (MMSE), a screening tool widely used for
impaired cognitive skills [14]. It is often used to identify
individuals in the early phase of dementia.
Brain magnetic resonance imaging
All subjects were scanned using a Siemens Magnetom
Trio 3 T MRI scanner(Erlangen, Germany) with an eight
channel head coil (Invivo, FL, USA) High-resolution
three-dimensional(192 sagittal slices; 256 x 256 acquisition
matrix) structural MRI scans of the brain were acquired
including T1-weighted magnetisation prepared rapid ac-
quisition gradient echo (MPRAGE) images (repetition
time (TR) = 1550 ms, echo time (TE) = 3.04, inversion time
(TI) = 800 ms; flip-angle = 9°; 1x1x1mm3), T2-weighted
turbo spin echo images (TR=3000 ms, TE=354 ms;
FOV=282 mm;1.1x1.1x1.1 mm3), and fluid-attenuated in-
version recovery (FLAIR) images (TR=6000 ms,
TE=353 ms, TI = 2200; FOV=282 mm;1.1x1.1x1.1 mm3).
Image pre-processing
Images were pre-processed using pipelines implemented
in Matlab, mainly SPM8 (Wellcome Department of Cog-
nitive Neurology, University College London, UK) rou-
tines to obtain anatomical point correspondence
between images. MPRAGE images were initially coregis-
tered to the Monteal Neurological Institute (MNI) tem-
plate image using a 6 parameter rigid transformation.
Subsequently, T2-weighted and FLAIR images were cor-
egistered to the corresponding MPRAGE image using a
6 parameter rigid transformation. All images were cor-
rected for spatial distortions due to non-linearity in the
gradient system of the scanner, and resliced to 1x1x1
mm3 resolution in MNI standard orientation.
Global tissue volumes
Brain tissue volumes, that included cortex, grey and
white matter were estimated from the MPRAGE image
with SIENAX, part of FSL, and were normalised for sub-
ject head size [15]. Intracranial volume was calculated by
multiplying the volumetric scaling factor with the intra-
cranial volume of the standard MNI template. Brain par-
enchymal fraction (BPF), a surrogate for brain atrophy
was determined as total brain volume/ICV.
White matter hyperintensities
WMH were defined as clearly hyperintense areas relative
to surrounding white matter on both FLAIR and
T2-weighted images and identified by simultaneous in-
spection of both images. Infarcts (areas that were hyper-
intense on T2-weighted imaging but with low signal
intensity on FLAIR and T1-weighted images and located
in a vascular distribution area) were noted but not
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volumes for the whole brain quantified automatically
using JIM (www.xinapse.com). Visual identification was
carried out by a single trained rater blinded to clinical
information.
The study was approved by the local ethics committee
and all patients gave written informed consent.
Statistical analysis
We investigated the association between P-NT-proBNP
and WMH and/or BPF in univariate linear regression
analyses in the 20 cases and also assessed the WMH
levels in patients divided according to P-NT-proBNP
tertiles. Furthermore, multivariate linear regression ana-
lyses were also performed with adjustment for age, sex
and CV risk factors. Importantly, due to our low number
of samples, we only included 2–3 risk factors in addition
to age and sex for every analysis. However, we did test to
see if various different combinations of various different
2–3 CV risk factors changed associations between P-
NT-proBNP and WMH and/or BPF. Included CV risk
factors were known diabetes duration, BMI, total choles-
terol, systolic blood pressure, HbA1c, presence of retin-
opathy, urinary albumin excretion rate, vibration
threshold, heart rate variation, CIMT, left ventricular
ejection fraction (LVEF), CCS and subclinical CAD. Par-
ticular the concomitant analyses with measures of sub-
clinical atherosclerosis (CIMT, LVEF, CCS and
subclinical CAD) were performed in order to test for a
possible common driver of both P-NT-proBNP and
WMH. Secondly, patients in groups with or without
CAD and age-matched controls were compared in rela-
tion to brain measurements. Comparisons between
groups were performed by an unpaired Student's t-test
or the Pearson Chi-test2 when appropriate. Data were
expressed as means and standard deviation (SD), except
for non-normally distributed variables, which were given
as medians and interquartile range. WMH volumes were
skewly distributed and we used log WMH, in addition to
medians (range), also given as geometric mean (SD) in
order to compare with other studies. Several controls
had no WMH, therefore we used log WMH (0 + 0.0001)
for all controls. All data were analyzed by using statis-
tical package for social sciences (SPSS) version 14 for
windows, and a P value less than 0.05 was considered as
statistically significant.
Results
Patient characteristics and brain structure
Clinical characteristics of all patients and cerebral MRI
measurements in all patients, in patients with or without
CAD and age and sex matched controls, respectively,
are summarized in Table 1. Of note, WMH were higher
and BPF was lower in our patients, and in particularpatients with CAD, compared to age and sex matched
controls, however not when adjusting for conventional
risk factors.
P-NT-proBNP, WMH volume and BPF
P-NT-proBNP was measured in all cases and distribu-
tion is shown in Table 1. A correlation in univariate lin-
ear regression analysis was found between P-NT-
proBNP and WMH volumes (r = 0.68, p = 0.001,
Figure 1). In an adjusted model that included age, sex,
total cholesterol and systolic blood pressure, P-NT-
proBNP remained predictive of WMH (r = 0.82,
p = 0.05). Importantly, when all the other previously
defined CV risk factors (known diabetes duration, total
cholesterol, BMI, systolic blood pressure, HbA1c, pres-
ence of retinopathy, urinary albumin excretion rate, vi-
bration threshold, heart rate variation, CIMT, LVEF,
CCS or the presence of asymptomatic CAD) were
included in the latter analysis instead of total cholesterol
and systolic blood pressure in various combinations as
previously defined, the association remained significant
(all p < 0.05). Interestingly, when CIMT was included in
addition to age, sex, cholesterol and systolic blood pres-
sure, the significance and association between P-NT-
proBNP and WMH increased (r = 0.94, p = 0.001). P-NT-
proBNP was also associated with BPF in univariate linear
regression analysis (r = 0.57, p = 0.009) but not after ad-
justment for sex and age (p = 0.23).
Patients were also divided into NT-proBNP tertiles
(<14.7, 14.7-57.4, and >57.4 ng/l, respectively), and
patients with high and intermediate P-NT-proBNP levels
had higher WMH volume (geometric mean[SD]; (2.86
[5.11] and 0.76[2.49], compared to patients with low P-
NT-proBNP(0.20[2.28] , p = 0.003, Figure 2), and this
was also significant when adjusting for age, sex and pres-
ence of CAD (p = 0.017).
Discussion
Principal findings
In twenty patients with type 2 diabetes with no history
of stroke, P-NT-proBNP was strongly associated with
volumes of white matter hyperintensities. Furthermore,
white matter hyperintensities were higher and brain par-
enchyma fraction was lower in our patients, and in par-
ticular patients with CAD, compared to age and sex
matched controls, however not when adjusting for con-
ventional risk factors.
Plasma NT-proBNP and white matter hypertensities
Our main finding that elevated P-NT-proBNP levels were
associated with presence and severity of WMH has to our
best knowledge not been described before. The association
was independent of all tested CV risk factors and particu-
lar age and systolic blood pressure, which are considered
Table 1 The clinical characteristics and cerebral measurements of all patients and patients with or without
asymptomatic coronary artery disease (CAD) defined as abnormal myocardial perfusion imaging and/or stenosis on
coronary angiography, and age and sex matched controls
All patients Controls p-values1 Patients without CAD Patients with. CAD p-values2
(n = 20) (n = 26) (n = 10)) (n = 10))
Sex no. (male%) 17 (76) 21 (81) 0.70 8 (80) 9 (90) 0.53
Age, years 57 (10) 52 (15) 0.28 51 (9) 63 (7) 0.005
Duration of diabetes, years 12 (6) 9 (6) 15 (7) 0.036
BMI, kg/m2 31.9 (4.3) 31.5 (4.3) 32.2 (4.6) 0.69
HbA1c , mmol/mol , (%) 63 (7.9) 53 (7.8) 64 (8.1) 0.66
Urinary albumin excretion rate, mg/24ha 103 (3 – 1263) 118 (42–618) 95 (3 – 1263) 0.37
P-creatinine, μmol/l 78 (20) 69 (17) 88 (18) 0.025
Systolic blood pressure, mmHg 133 (17) 127 ± 15 138 (18) 0.20
Total cholesterol, mmol/l 3.7 (0.9) 3.8 ± 1.1 3.5 (0.7) 0.43
Vibratory perception threshold
mV – mean of both sides
31 (15) 22 (12) 40 (13) 0.004
Heart rate variation during deep
breathing, bpma
8 (2–29) 11 (5–29) 5 (2–11) 0.004
Retinopathy no. (%) 11 (55) 4 (40) 7 (70) 0.18
Oral antidiabetic medication no. (%) 18 (90) 9 (90) 90 (90) 1.0
Insulin treatment no. (%) 14 (70) 6 (60) 8 (80) 0.33
RAAS blockade no. (%) 20 (100) 10 (100) 10 (100) 1.0
Statin therapy no. (%) 20 (100) 10 (100) 10 (100) 1.0
Aspirin therapy no. (%) 20 (100) 10 (100) 10 (100) 1.0
Beta-blocker therapy no. (%) 2 (10) 0 (0) 2 (20) 0.14
Calcium channel blockers no. (%) 7 (35) 1 (10) 6 (60) 0.015
Use of diuretics no. (%) 11 (55) 5 (50) 6 (60) 0.65
Current smoker no. (%) 5 (25) 3 (30) 2 (20) 0.60
Carotid intima-media thickness, mm 0.73 (0.14) 0.70 (0.13) 0.77 (0.14) 0.34
NT-proBNP, ng/la 23.9 (5.1-357,6) 7.6 (5.1-29.1) 125.4 (15.8-357.6) nr
MMSEa 30 (25–30) 30 (28–30) 28 (25–30) 0.035
Cerebral MRI measurements
White matter hyperintensities, mlb 0.79 (4.89) 0.002 (139) 0.0001 0.34 (2.75) 1.85 (5.17) 0.012
White matter hyperintensities, mla,b 0.48 (0.29-2.92) 0 (0–1.40) 0.0001 0.42 (0.13-0.78) 2.46 (0.36-2.92) 0.012
Brain parenchymal fraction 0.77 (0.04) 0.82 (0.05) 0.001 0.79 (0.04) 0.74 (0.02) 0.002
Intracranial volume (ICV), ml 1443.4 (123.9) 1441.5 (285.7) 0.98 1451.0 (104.7) 1435.8 (146.0) 0.79
Grey matter volume per ICV,% 38.9 (2.7) 42.6 (3.2) 0.0001 40.2 37.6 0.029
White matter volume per ICV,% 37.6 (2.3) 39.1 (2.1) 0.027 39.0 36.3 0.006
Cortex volume per ICV,% 29.9 (2.3) 33.0 (2.7) 0.0001 31.0 28.8 0.033
Ventricular volume per ICV,% 3.4 (1.3) 2.5 (0.8) 0.002 2.9 4.2 0.024
Data are expressed as means (standard deviation [SD]) or medians (interquartile range) a. Not relevant (nr).
WMH volumes b are both expressed as geometric mean (SD) values or medians (interquartile range) a in order to compare with other studies. Several controls had
no WMH and therefore we used log WMH (0 + 0.0001) for all controls. The majority of controls had no signs of WMH (69%) but in contrast all patients had WMH.
P-values reflect comparison between patients and controls1, and patients with or without CAD2.
These comparisons were all non-significant when adjustment for age and sex.
Mini mental state examination (MMSE).
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Figure 1 Univariate linear regression analysis with the logarithm of plasma NT-proBNP (ng/l) in relation to the logarithm of white
matter hyperintensities in 20 patients with type 2 diabetes.
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between P-NT-proBNP and WMH was strengthened and
not attenuated by the addition of CV risk factors and in
particular CIMT, and this may suggest that the cause is
not related to an age systemic atherosclerosis but indeed
organ heart and brain specific, therefore linking the heart
with the brain. In humans the left ventricle is the mainFigure 2 A scatter plot correlation, showing white matter hyperinten
intermediate and high plasma NT-proBNP levels (tertile values), respe
p= 0.003).source of P-NT-proBNP with increased myocyte stretch
or myocardial ischemia. It therefore seemed unlikely,
based on physiology that elevated P-NT-proBNP from the
heart per se directly promoted WMH or cerebrovascular
disease in the present study. In contrast, heart disease
such as heart failure or presence of atrial fibrillation that
are known determinants of higher P-NT-proBNP levelssities in 20 patients with type 2 diabetes and with low,
ctively, (horizontal bar is geometric mean among the groups,
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common driver of both elevated P-NT-proBNP and
WMH [7]. Our patients, however, were without acute ill-
ness and had normal ejection fraction without atrial fibril-
lation or valvular disease, and patients also had lower
levels of P-NT-proBNP than seen in congestive heart fail-
ure [11]. Furthermore, we performed concomitant ana-
lyses with measures of subclinical heart disease, and the
association between P-NT-proBNP and WMH remained
significant after adjustment for LVEF, CCS and asymptom-
atic CAD. Along that line when patients with CAD were
excluded, the association between P-NT-proBNP and
WMH actually persisted. This is particular important,
since the differences in P-NT-proBNP levels between
patients with and without CAD were large and this could
drive a false association between P-NT-proBNP and
WMH. Of note, we only included patients with or without
previously screen detected asymptomatic CAD in order to
include patients with a wide risk profile. Accordingly, our
present study suggests that the cause of the association
between P-NT-proBNP and WMH is not explained by a
common typical CV or heart disease driver, therefore pos-
sibly directly linking P-NT-proBNP and WMH. Along
that line, recent studies have documented that plasma
brain natiurectic peptide (BNP) itself increases the risk of
stroke [16]. WMH are commonly found on MRI of elderly
individuals with frequencies ranging from 11-21% at age
60 to 94% at age 82 [4]. Although often referred to as 'inci-
dental', WMH have been associated with decline in cogni-
tive function in independently living elderly populations
and with a two-fold increased risk of dementia or stroke
[4]. Furthermore, WMH are regarded as expressions of
chronic hypoperfusion and small vessel cerebral disease.
Small vessel cerebral disease is the most prevalent asymp-
tomatic neurological disease, its incidence reported to be
6- to 10-fold that of symptomatic stroke [9,10]. Presence
of WMH has been reported to predict a three-fold
increased risk of stroke and two-fold increased risk of
mortality in the general population [4]. In the recent Fra-
mingham Offspring Stroke Study, the presence of WMH
predicted CV mortality and this was independent of risk
factors and strokes or dementia [17]. Following the discus-
sion of the mechanism underlying the relationship be-
tween P-NT-proBNP and WMH, the reverse could also
be true; WMH induced elevated P-NT-proBNP levels
through abnormal neuroendocrine signals to the cardiac
ventricles and thereby functional asymptomatic heart fail-
ure [7]. Accordingly, the chronic cerebral hypoperfusion
seen in patients with WMH could indirectly promote NT-
proBNP realise from the heart. Our measurement of
cardiac autonomic neuropathy (heart rate variability),
however, did not change the association between P-NT-
proBNP and WMH in the present study. Increased P-NT-
proBNP levels could, however, also reflect other counteractions to the damages associated with WMH and accord-
ingly mediated through other pathways. Along that line,
other studies have suggested that BNP include several
actions in addition to vasodilation and promotion of natri-
uresis and diuresis such as inhibition of the sympathetic
nervous system and inhibition of several hormone sys-
tems, including the renin-angiotensin-aldosterone-system
(RAAS), endothelins, cytokines, and vasopressin [18,19].
Finally, the correlation between P-NT-proBNP and
WMH could also be brain to brain instead of heart to
brain. Along that line, damage or hypoperfusion of the
brain (WMH) might directly induce realise of NT-
proBNP from the brain [20]. Brain natriuretic peptide
(BNP) was actually first described in the porcine brain
and accordingly later localized in the hypothalamus,
thalamus, cerebellum, pons and cortex of the human
brain [20]. Few studies have investigated BNP and NT-
proBNP from the brain in disease. Specifically, in rats
status epilepticus induced increase in plasma ANP (8),
and occlusion of the middle cerebral artery stimulates
BNP mRNA expression in rat brain tissues [21]. In
humans, the BNP gene promoter region contains a
hypoxia-inducible factor-1 binding site, which activates
BNP expression [22], and in patients with subarachnoid
hemorrhage plasma BNP concentrations were higher
than controls. Some studies have also shown that P-NT-
proBNP is increased in patients with acute ischemic
stroke [6,7,23-25] but these studies may not have con-
vincingly demonstrated that this association is independ-
ent from heart disease. In contrast, Tomati et al.
examined all included patients with acute stroke with
echocardiography in order to exclude the presence of
heart disease and hereby investigate if BNP levels were
elevated in patients with acute stroke, independently of
heart disease. The study demonstrated that plasma BNP
levels were indeed associated with the severity of cere-
brovascular disease and particular volume of brain in-
farct size. One human CT study also recently suggested
that the ischemic brain tissue per se release NT-proBNP
into the circulation [26]. Importantly, all our patients
were without acute illnesses; since acute disease such as
stroke might be a condition that per se with sympathetic
and catecholamines activity, cause stress of the heart
and therefore BNP secretion. In contrast, our patients
with CAD had higher WMH and lower BPF, however no
longer after adjustment for age and sex (Table 1). Our
study also demonstrated that WMH is higher and BPF
lower in our patients compared to age-matched controls,
where 69% had no signs of WMH.
Clinical implications
All our patients had microalbuminuria and several stud-
ies have demonstrated that microalbuminuria identifies a
subgroup of patients with increased morbidity and
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gest that P-NT-proBNP can further stratify the group
into patients with high or low risk for CV events [1,3,5].
Specifically, we have previously identified P-NT-proBNP
as a powerful predictor of all cause and cardiovascular
mortality that included strokes in patients with type 2
diabetes [5]. In that study, 80% of patients in the upper
P-NT-proBNP tertile died, compared to 30% of patients
in the lower tertile during 15 years of follow-up. The
cause of poor prognosis in patients with elevated P-NT-
proBNP is not known. We therefore performed the
above described cross-sectional study of 200 patients
with microalbuminuria and in this study, which exam-
ined patients for subclinical CAD and CV disease, we
demonstrated no independent correlations between P-
NT-proBNP and measurements of peripheral systolic
blood pressure, CIMT, CCS, MPI, CAG or echo abnor-
malities [11-13]. P-NT-proBNP levels, however, have
been shown by others to correlate with CIMT [27], CCS
[28], MPI [29], CAG [30] and echo abnormalities [31] in
other populations. Along that line, all our patients
received intensive multifactorial intervention at Steno
Diabetes Center for years before entering the study and
this intervention aimed at CV prevention includes
improved glycemic, lipid, and blood pressure control, as
well as antithrombotic therapy and lifestyle modification
according to international guidelines [32]. Intensive
multifactorial treatment according to the Steno-2 trail
reduces CV disease and mortality with 50% [2]. Of note,
the medical treatment in our large cohort included sta-
tins (95% of patients), aspirin (92%), and RAAS-blocking
agents (98%) and yielded mean total cholesterol levels of
3.7 mM, arterial blood pressures of 133/75 mmHg, and
haemoglobinA1c levels of 53 mmol/mol (7.9%), respect-
ively. We have therefore speculated that the intensive
multifactorial medical treatment may be responsible for
a weakening of the associations currently found between
P-NT-proBNP levels and the previously described mea-
surements of subclinical CAD and CV disease [11-13].
The Steno-2 trial showed that P-NT-proBNP levels
might still hold prognostic capability despite multifactor-
ial treatment [33]. Along that line, the association be-
tween P-NT-proBNP and WMH in the present study
could suggest that the residual risk seen in these patients
could be cerebrovascular and that this risk is revealed
with increased levels of P-NT-proBNP. If P-NT-proBNP
in general can be used as an independent biomarker in
the detection of subclinical WMH or cerebrovascular
disease is, however, not known. Along that line, our
present study is small and included a relative selected
population of type 2 diabetic patients. For an example,
the intensive medical therapy prescribed in our patients
but also the selection of high risk CV patients with
microalbuminuria and/or asymptomatic CAD. Alongthat line, the confounders on P-NT-proBNP levels could
be even more pronounced in complicated CV patients,
and therefore more than we were able to adjust for.
Today, it is generally accepted that the P-NT-proBNP
assay may be useful in the screening, diagnosis and per-
haps monitoring of patients with heart failure. In the
general population, BNP inversely correlates with hyper-
insulinemia but in diabetic patients P-NT-proBNP levels
are increased compared to controls, and in addition
BNP levels are altered by several factors in stroke
patients [34-36]. P-NT-proBNP is a prognostic marker
of CV disease in several populations including diabetic
patients, and perhaps also a diagnostic tool for LV dys-
function in diabetic patients [5,31]. As described above,
recent studies have demonstrated that BNP might also
be important in patients with stroke. Specifically, Saritas
et al., showed that plasma BNP levels could serve as a
measurement of the severity and clinical progression in
stroke patients [37]. Furthermore, the Framingham Off-
spring Study demonstrated that BNP offered improve-
ment in the accuracy of stroke risk [16]. This could also
be true in diabetic patients but is not formally proven
[5]. Finally, it is important to note that few studies have
investigated if WMH or other cerebrovascular disease in
these patients on intensive medical therapy could serve
a CV preventive treatment target. In one study, more ag-
gressive antihypertensive treatment was associated with
reduced progression in WMH but if this reduction is
associated with reduced risk is not known [38]. Accord-
ingly, the clinical impact of the presence of WMH and
the true meaning of NT-proBNP and WMH associations
need to be investigated in larger and longitudinal
studies.
Strengths and limitations
Our detection of brain structure in the present study
was performed with 3D MRI scan, which is a well estab-
lished, recognized and accurate strong non-invasive mo-
dality for these measurements. The MRI is sensitive with
a three-dimensional quantification and low covariability
[39]. Most studies that include MRI measurements in
patients with diabetes are from subpopulations [40] and
fewer studies report volumetric measurements as in the
present study [41,42]. Although our study only included
twenty patients with diabetes, we demonstrated a broad
variation of WMH and brain volumes among our
patients that were selected among 200 patients with or
without asymptomatic CAD in order to include patients
with a wide-ranging CV risk profile. The several multi-
variate analyses we performed as described in various
combination of 2–3 CV risk factors in addition to age
and sex, due to the relative low sample size, should obvi-
ously be interpreted with caution and we did not test for
the multiple testing in these analyses.
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We demonstrated for the first time that plasma NT-
proBNP was independently associated with white matter
hyperintensities in asymptomatic type 2 diabetec
patients with no history if stroke. The association was
strengthened and not attenuated with the addition of
CV risk factors and particular carotid artery intima
media thickness, suggesting a linkage between heart and
brain disease. We were however, not able to demonstrate
a common driver of both P-NT-proBNP and white mat-
ter hypertensities. Finally, white matter hyperintensities
were higher and brain parenchyma fraction was lower in
our patients, and in particular patients with CAD, com-
pared to age and sex matched controls, however not
when adjusting for conventional risk factors.
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